Yes, Ritalin is still prescribed and remains FDA-approved for treating ADHD in patients six and older, as well as narcolepsy. Its prescribing label was most recently updated in October 2023. That said, Ritalin’s share of the stimulant market has shifted considerably over the past decade, and the landscape around it has changed in ways worth understanding.
How Widely Ritalin Is Prescribed Today
Methylphenidate, the active ingredient in Ritalin, accounted for about 22% of all stimulant prescriptions dispensed in 2023, with roughly 16.6 million prescriptions filled that year. That’s a significant number, but it places methylphenidate well behind amphetamine-based medications like Adderall, which made up 49% of stimulant prescriptions. Lisdexamfetamine (Vyvanse) held another 19%.
So while Ritalin and its generic equivalents are far from obsolete, they’re no longer the default first choice they once were. Amphetamine-based stimulants have become the most commonly prescribed option for ADHD in both children and adults.
Why Doctors Still Choose It
Every person responds to stimulant medications a little differently. Some people do better on methylphenidate-based drugs, others on amphetamine-based ones, and there’s no reliable way to predict which will work best before trying one. That individual variability is the main reason Ritalin remains a core option.
Methylphenidate works by blocking the recycling of two brain chemicals: dopamine and norepinephrine. When these chemical messengers hang around longer in the spaces between neurons, attention, focus, and impulse control improve. It has a stronger effect on dopamine recycling in lab settings, though in the living brain it also has a notable impact on norepinephrine.
A large network meta-analysis published in The Lancet Psychiatry compared ADHD medications head to head. In children and adolescents, amphetamines showed a somewhat larger reduction in core ADHD symptoms than methylphenidate when rated by clinicians. But when teachers rated the same children’s behavior in the classroom, methylphenidate was one of only two drugs that clearly outperformed a placebo. In adults, amphetamines again had a larger average effect size, but methylphenidate still produced meaningful improvement over placebo. The differences between the two drug classes, while real, are modest enough that switching from one to the other is standard practice when the first choice doesn’t work well or causes too many side effects.
Available Formulations
Ritalin itself comes in immediate-release tablets that last about two to three hours per dose, meaning most people need to take it two or three times a day. For many patients, that dosing schedule is inconvenient, especially for children in school. That’s one reason extended-release methylphenidate formulations have become more popular. These include brand names like Concerta, Ritalin LA, Aptensio XR, and Quillivant XR (a liquid). Extended-release versions use specialized capsule designs that release the drug gradually, covering most of the day with a single morning dose.
Generic methylphenidate is widely available in both immediate-release and extended-release forms, which generally costs significantly less than the brand-name versions.
Common Side Effects
The most frequently reported side effects are loss of appetite, weight loss, trouble falling or staying asleep, stomach pain, headache, and irritability. These tend to be dose-related, meaning they often improve if the dose is lowered.
Less common but more serious effects include a fast or irregular heartbeat, chest pain, mood changes (including new or worsening depression or unusually elevated mood), and in rare cases, hallucinations or tics. Circulation problems in the fingers and toes, marked by color changes or numbness, can also occur.
In children, one specific concern is growth. Methylphenidate can slow height and weight gain, so pediatricians typically monitor a child’s growth trajectory at regular visits. Some families choose to take breaks from the medication during summer months partly for this reason, though that’s a decision made on a case-by-case basis.
Prescribing Restrictions
Methylphenidate is classified as a Schedule II controlled substance by the DEA, the same category as amphetamine-based stimulants. This means prescriptions cannot include refills. You need a new prescription each time, and in most states, the prescription expires after a set period (often 90 days) if not filled. Some states allow electronic prescribing for Schedule II drugs, while others still require additional verification steps. These restrictions exist because methylphenidate does carry a risk of misuse, though when taken as prescribed for ADHD, dependence is uncommon.
Current Shortage Issues
If you’ve had trouble filling a methylphenidate prescription recently, you’re not alone. Several extended-release methylphenidate products have been on shortage. The causes vary by manufacturer: some cite increased demand, others point to manufacturing delays or shortages of the active ingredient itself. At least one manufacturer (Sun Pharma) has discontinued its extended-release tablets entirely, and Teva discontinued several strengths of its extended-release capsules in late 2024.
Some manufacturers are still shipping product but allocating limited supplies. The immediate-release tablets and certain specialty formulations (like chewable tablets and liquid suspensions) have generally been easier to find. If your pharmacy can’t fill your specific prescription, your doctor can often switch you to an equivalent dose from a different manufacturer or a different release mechanism.
Uses Beyond ADHD
While ADHD is the primary reason methylphenidate is prescribed, it also has FDA approval for narcolepsy. Beyond those two indications, doctors prescribe it off-label for several other situations. In palliative care and among older adults with serious medical illness, methylphenidate is used to treat fatigue, apathy, and depressive symptoms, largely because it works faster than traditional antidepressants. It has also been used to counteract sedation from opioid pain medications in terminally ill patients, to address cognitive slowing after traumatic brain injury or stroke, and to manage apathy in Alzheimer’s disease. These off-label uses are less common but reflect how versatile the medication remains in clinical practice.